Your session is about to expire
← Back to Search
Sacubitril-Valsartan for Hemodialysis Patients
Study Summary
This trialwill test how a drug affects people with kidney failure and how safe it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on a thrice-weekly hemodialysis schedule.I am scheduled for a kidney transplant within the next 4 months.I produce less than 100 mL of urine daily.I haven't used any experimental drugs or devices in the last 12 weeks.I am 18 or older and started hemodialysis within the last 90 days.I have not taken sacubitril/valsartan in the last 30 days.I am planning to undergo a procedure to improve blood flow to my heart or brain within 4 months.I have a serious heart valve problem or a type of heart muscle disease.I have had fainting spells due to an untreated heart rhythm problem in the last 3 months.I haven't had a heart attack, stroke, or major heart-related surgery in the last month.I haven't taken any ACE inhibitors in the last 36 hours.I am using two effective birth control methods if I can become pregnant.I have had a heart device implanted recently or plan to soon.My blood pressure has been stable and above 110 mmHg before dialysis, without needing medication for low blood pressure.I have a slow heartbeat or heart block without a pacemaker.I am mentally capable of making my own health decisions.I haven't had cancer in the last year, except for certain skin cancers or cervical cancer that's considered cured.I do not have severe liver disease or significantly high liver enzyme levels.
- Group 1: sacubitril/valsartan
- Group 2: placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this study still have open enrollment?
"Affirmative. Clinicaltrials.gov conveys that the trial, which was initially shared on October 11th 2022 and recently modified on October 23rd 2022, is actively searching for 100 participants from a solitary medical site."
To what extent is this trial being participated in by individuals?
"Affirmative. Clinicaltrials.gov data confirms that this clinical trial, which was first posted on October 11th 2022 is actively recruiting patients. 100 individuals need to be enrolled from a single site."
Is sacubitril/valsartan a viable treatment option with minimal risk?
"The safety of sacubitril/valsartan has been rated 2, as the clinical trial is currently in its second phase. At this point there is evidence to demonstrate safety but not efficacy."
Share this study with friends
Copy Link
Messenger